Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Fu...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 1,396
- Institution
- Pfizer (Germany)
External Links
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.